Biodesix Inc (BDSX) Stock Price, Quote & News

Company Profile

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy,...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 303 417 0500

Fax: 866 432 3338

Website: www.biodesix.com

Address:

919 West Dillon Road, Louisville, United States

MoneyMacG Aug. 26 at 7:23 PM

$QNCX $GIBO $BDSX $APLM $SAIH gem

0 · Reply

healthcareguru Aug. 26 at 4:19 PM

$BDSX Despite this huge run, stock is still not overbought and is still DIRT CHEAP at 2.5x EV/sales vs comp group 4-6x…send her to $50!! 🦾🔥 $XLV $IWM $XBI

0 · Reply

Kauaibeta Aug. 26 at 3:18 PM

$BDSX nice double but Schuler needs a lot more for me to cover the axdx debacle

0 · Reply

Johndoe456 Aug. 21 at 1:27 PM

$BDSX

2 · Reply

MoneyMacG Aug. 20 at 6:08 PM

$INTG $FTH $GIBO $WETO $BDSX score

0 · Reply

MoneyMacG Aug. 17 at 9:19 PM

$APLM $BDSX $BBGI $CHRN !

0 · Reply

MoneyMacG Aug. 17 at 7:32 PM

$DFNS $GBIO $APLM $BDSX $CHRN gem(((((((

0 · Reply

FilingTracker Aug. 12 at 9:56 PM

$BDSX Purchase by 10% owner: https://filingtracker.ai/filing/1021412/0000905148-26-003599?doc=form4.xml

0 · Reply

_ProfessorGamma Aug. 9 at 1:50 PM

$BDSX Better shape than people admit

0 · Reply

CamilaCruze Aug. 9 at 12:07 AM

$BDSX 2026 guidance: Raised to $108–114M, 25%🚀

0 · Reply

Biodesix Transcript: Canaccord Genuity's 46th Annual Growth Conference

2026-08-10T11:07:24.000Z - 16 days ago

Biodesix price target raised to $35 from $27 at Canaccord

2026-08-06T16:35:23.000Z - 20 days ago

Biodesix price target raised to $27 from $26 at H.C. Wainwright

Aug 5, 2026, 4:30 PM EDT - 21 days ago

Biodesix Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 21 days ago

Biodesix Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 21 days ago

Biodesix Quarterly report: Q2 2026

Aug 5, 2026, 4:01 PM EDT - 21 days ago

Biodesix Announces Second Quarter 2026 Results and Highlights

Aug 4, 2026, 6:00 AM EDT - 22 days ago

Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

Jul 22, 2026, 6:00 AM EDT - 5 weeks ago

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-07-09T13:50:25.000Z - 6 weeks ago

Biodesix management to meet virtually with Craig Hallum

2026-06-24T22:25:11.000Z - 2 months ago

Roth starts Biodesix at Buy, says positioned to deliver durable growth

2026-06-24T20:30:27.000Z - 2 months ago

Biodesix initiated with a Buy at Roth Capital

2026-06-18T10:55:38.000Z - 2 months ago

Biodesix price target raised to $27 from $22 at Canaccord

2026-06-15T10:15:54.000Z - 2 months ago

Biodesix initiated with a Buy at H.C. Wainwright

Jun 3, 2026, 3:00 PM EDT - 3 months ago

Biodesix Transcript: 46th Annual William Blair Growth Stock Conference

2026-05-21T20:46:14.000Z - 3 months ago

Biodesix files to sell 375,000 shares of common stock for holders

May 21, 2026, 8:00 AM EDT - 3 months ago

Biodesix Registration statement: Registration filing

May 21, 2026, 6:00 AM EDT - 3 months ago

Biodesix to Participate in Upcoming Investor Conferences

May 11, 2026, 9:17 AM EDT - 3 months ago

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

2026-05-05T10:50:00.000Z - 4 months ago

Biodesix price target raised to $22 from $20 at Canaccord

2026-05-04T20:30:28.000Z - 4 months ago

Biodesix reports Q1 EPS (81c) vs. ($1.52) last year

May 4, 2026, 4:30 PM EDT - 4 months ago

Biodesix Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 4 months ago

Biodesix Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 4 months ago

Biodesix Quarterly report: Q1 2026

2026-05-04T20:28:11.000Z - 4 months ago

Biodesix raises FY26 revenue view to $108M-$114M from $106M-$112M

May 4, 2026, 4:01 PM EDT - 4 months ago

Biodesix Announces First Quarter 2026 Results and Highlights

May 4, 2026, 7:00 AM EDT - 4 months ago

Biodesix Slides: Corporate presentation

Apr 20, 2026, 6:00 AM EDT - 4 months ago

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

Apr 9, 2026, 1:19 PM EDT - 4 months ago

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Biodesix Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Biodesix Proxy statement: Proxy filing

Apr 6, 2026, 11:43 AM EDT - 5 months ago

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

Mar 20, 2026, 8:06 AM EDT - 5 months ago

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

Mar 11, 2026, 12:00 PM EDT - 6 months ago

Biodesix Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 3, 2026, 2:30 PM EST - 6 months ago

Biodesix Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-27T10:00:18.000Z - 6 months ago

Biodesix upgraded to Outperform from Market Perform at William Blair

Feb 26, 2026, 4:30 PM EST - 6 months ago

Biodesix Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

Biodesix Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

Biodesix Earnings release: Q4 2025

2026-02-26T21:29:27.000Z - 6 months ago

Biodesix sees FY26 revenue $106M-$112M, consensus $105.9M

2026-02-26T21:13:01.000Z - 6 months ago

Biodesix reports Q4 EPS (49c) vs. ($1.13) last year

Feb 26, 2026, 4:01 PM EST - 6 months ago

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

Feb 12, 2026, 6:00 AM EST - 6 months ago

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

2026-01-12T16:55:18.000Z - 8 months ago

Biodesix trading resumes

2026-01-12T16:50:32.000Z - 8 months ago

Biodesix trading halted, volatility trading pause

2026-01-12T11:05:50.000Z - 8 months ago

Biodesix sees Q4 revenue $28.8M, consensus $25.02M

Jan 12, 2026, 6:00 AM EST - 8 months ago

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

Dec 3, 2025, 8:22 AM EST - 9 months ago

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Nov 3, 2025, 4:30 PM EST - 10 months ago

Biodesix Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Biodesix Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 10 months ago

Biodesix Earnings release: Q3 2025

2025-11-03T21:21:42.000Z - 10 months ago

Biodesix reports Q3 EPS ($1.16), consensus ($1.51)

Nov 3, 2025, 4:01 PM EST - 10 months ago

Biodesix Announces Third Quarter 2025 Results and Highlights

Oct 30, 2025, 6:17 AM EDT - 10 months ago

Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting

Oct 22, 2025, 6:17 AM EDT - 11 months ago

Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays

Oct 20, 2025, 6:00 AM EDT - 11 months ago

Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 15, 2025, 6:09 AM EDT - 11 months ago

Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting

Oct 6, 2025, 10:13 AM EDT - 11 months ago

Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit

Sep 11, 2025, 8:00 AM EDT - 1 year ago

Biodesix Announces One-for-Twenty Reverse Stock Split

Sep 5, 2025, 6:00 AM EDT - 1 year ago

Biodesix to Participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference

Aug 19, 2025, 9:47 AM EDT - 1 year ago

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Biodesix Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Biodesix Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Biodesix Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Biodesix Earnings release: Q2 2025

Aug 7, 2025, 4:06 PM EDT - 1 year ago

Biodesix Announces Second Quarter 2025 Results and Highlights

Aug 6, 2025, 6:00 PM EDT - 1 year ago

Biodesix Slides: Corporate Presentation

Aug 5, 2025, 6:00 AM EDT - 1 year ago

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 6:00 AM EDT - 1 year ago

Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 10, 2025, 6:17 AM EDT - 1 year ago

Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs

Jun 4, 2025, 10:20 AM EDT - 1 year ago

Biodesix Transcript: 45th Annual William Blair Growth Stock Conference

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Biodesix Slides: Corporate Presentation

May 22, 2025, 5:03 PM EDT - 1 year ago

Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

May 15, 2025, 6:00 AM EDT - 1 year ago

Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS

May 14, 2025, 4:01 PM EDT - 1 year ago

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

May 13, 2025, 4:30 PM EDT - 1 year ago

Biodesix Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Biodesix Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Biodesix Earnings release: Q1 2025

May 13, 2025, 4:01 PM EDT - 1 year ago

Biodesix Announces First Quarter 2025 Results and Highlights

Apr 29, 2025, 6:00 AM EDT - 1 year ago

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Biodesix Proxy statement: Proxy Filing

Apr 23, 2025, 6:00 AM EDT - 1 year ago

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Biodesix Proxy statement: Proxy Filing

Mar 5, 2025, 1:50 PM EST - 1 year ago

Biodesix Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 4:30 PM EST - 1 year ago

Biodesix Earnings Call Transcript: Q4 2024

Mar 3, 2025, 4:30 PM EST - 1 year ago

Biodesix Annual report: Q4 2024

Mar 3, 2025, 4:30 PM EST - 1 year ago

Biodesix Earnings release: Q4 2024

Mar 3, 2025, 4:01 PM EST - 1 year ago

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

Feb 26, 2025, 6:00 AM EST - 1 year ago

Biodesix to Present at TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 6:00 AM EST - 1 year ago

Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Jan 10, 2025, 6:00 AM EST - 1 year ago

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

Jan 7, 2025, 6:00 AM EST - 1 year ago

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Biodesix Earnings Call Transcript: Q3 2024

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Biodesix Quarterly report: Q3 2024

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Biodesix Earnings release: Q3 2024

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Biodesix Registration statement: Registration Filing

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Biodesix Registration statement: Registration Filing

Nov 1, 2024, 6:00 AM EDT - 1 year ago

Biodesix Announces Third Quarter 2024 Results and Highlights

Oct 29, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Participate in Three Investor Conferences in November

Oct 18, 2024, 6:00 AM EDT - 2 years ago

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024

Oct 7, 2024, 6:00 AM EDT - 2 years ago

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study

Sep 5, 2024, 6:00 AM EDT - 2 years ago

Biodesix to Present at Two Investor Conferences in September

Aug 14, 2024, 1:00 PM EDT - 2 years ago

Biodesix Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Biodesix Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Biodesix Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Biodesix Earnings release: Q2 2024

Aug 7, 2024, 4:01 PM EDT - 2 years ago

Biodesix Announces Second Quarter 2024 Results and Highlights

Aug 6, 2024, 6:00 AM EDT - 2 years ago

Biodesix to Present at Canaccord Genuity's 44th Annual Growth Conference

Jul 24, 2024, 6:00 AM EDT - 2 years ago

Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024

Jun 18, 2024, 8:13 AM EDT - 2 years ago

Biodesix Named to Inc. Magazine's 2024 “Best Workplaces”

Jun 6, 2024, 8:30 AM EDT - 2 years ago

Biodesix Transcript: Jefferies Global Healthcare Conference

Jun 4, 2024, 11:40 AM EDT - 2 years ago

Biodesix Transcript: The 44th Annual William Blair Growth Stock Conference

May 28, 2024, 6:00 AM EDT - 2 years ago

Biodesix to Participate in Two Investor Conferences in June

May 24, 2024, 8:00 AM EDT - 2 years ago

Biodesix Registration statement: Registration Filing

May 21, 2024, 6:00 AM EDT - 2 years ago

Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting

May 14, 2024, 1:35 PM EDT - 2 years ago

Biodesix Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 4:30 PM EDT - 2 years ago

Biodesix Earnings Call Transcript: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Biodesix Quarterly report: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Biodesix Earnings release: Q1 2024

May 8, 2024, 4:01 PM EDT - 2 years ago

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management

MoneyMacG Aug. 26 at 7:23 PM

$QNCX $GIBO $BDSX $APLM $SAIH gem

0 · Reply

healthcareguru Aug. 26 at 4:19 PM

$BDSX Despite this huge run, stock is still not overbought and is still DIRT CHEAP at 2.5x EV/sales vs comp group 4-6x…send her to $50!! 🦾🔥 $XLV $IWM $XBI

0 · Reply

Kauaibeta Aug. 26 at 3:18 PM

$BDSX nice double but Schuler needs a lot more for me to cover the axdx debacle

0 · Reply

Johndoe456 Aug. 21 at 1:27 PM

$BDSX

2 · Reply

MoneyMacG Aug. 20 at 6:08 PM

$INTG $FTH $GIBO $WETO $BDSX score

0 · Reply

MoneyMacG Aug. 17 at 9:19 PM

$APLM $BDSX $BBGI $CHRN !

0 · Reply

MoneyMacG Aug. 17 at 7:32 PM

$DFNS $GBIO $APLM $BDSX $CHRN gem(((((((

0 · Reply

FilingTracker Aug. 12 at 9:56 PM

$BDSX Purchase by 10% owner: https://filingtracker.ai/filing/1021412/0000905148-26-003599?doc=form4.xml

0 · Reply

_ProfessorGamma Aug. 9 at 1:50 PM

$BDSX Better shape than people admit

0 · Reply

CamilaCruze Aug. 9 at 12:07 AM

$BDSX 2026 guidance: Raised to $108–114M, 25%🚀

0 · Reply

EarningsInsider Aug. 5 at 9:16 PM

https://www.marketbeat.com/earnings/reports/2026-8-5-biodesix-inc-stock/ $BDSX Biodesix Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 5 at 8:08 PM

$BDSX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.71 up 55.62% YoY • Reported revenue of $26.86M up 34.18% YoY • Biodesix expects total revenue of $108-114 million for full year 2026, with the midpoint representing approximately 25% growth over 2025, and maintains gross margin guidance of approximately 80% for 2026.

0 · Reply

LewisDaKat Aug. 4 at 10:30 AM

$BDSX Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference https://marketwirenews.com/stock/bdsx/news/biodesix-to-participate-in-canaccord-genuity-s-46th--8701201533428978.html?utm_source=stocktwits

0 · Reply